AR and metastatic neoplasm: Second‐generation AR pathway inhibitors (ARPIs), including non‐steroidal competitive antagonists such as enzalutamide, apalutamide and darolutamide, achieve more potent AR blockade than earlier agents (e.g., bicalutamide and flutamide) and have demonstrated survival benefits in metastatic disease [22, 23].